0 4 Oct2 oct2 NN 5 20 transactivation transactivation NN 21 25 from from IN 26 27 a a DT 28 34 remote remote JJ 35 43 enhancer enhancer NN 44 52 position position NN 53 61 requires require VBZ 62 63 a a DT 64 81 B-cell-restricted b-cell-restricted JJ 82 90 activity activity NN 90 91 . . . 93 101 Previous previous JJ 102 116 cotransfection cotransfection NN 117 128 experiments experiment NNS 129 132 had have VBD 133 145 demonstrated demonstrate VBN 146 150 that that IN 151 158 ectopic ectopic JJ 159 169 expression expression NN 170 172 of of IN 173 176 the the DT 177 196 lymphocyte-specific lymphocyte-specific JJ 197 210 transcription transcription NN 211 217 factor factor NN 218 222 Oct2 oct2 NN 223 228 could could MD 229 240 efficiently efficiently RB 241 249 activate activate VB 250 251 a a DT 252 260 promoter promoter NN 261 271 containing contain VBG 272 274 an an DT 275 282 octamer octamer NN 283 288 motif motif NN 288 289 . . . 290 294 Oct2 oct2 NN 295 305 expression expression NN 306 309 was be VBD 310 316 unable unable JJ 317 319 to to TO 320 329 stimulate stimulate VB 330 331 a a DT 332 344 multimerized multimerized JJ 345 352 octamer octamer NN 353 361 enhancer enhancer NN 362 369 element element NN 370 372 in in IN 373 377 HeLa HeLa NNP 378 383 cells cell NNS 383 384 , , , 385 392 however however RB 392 393 . . . 394 396 We we PRP 397 401 have have VBP 402 408 tested test VBN 409 410 a a DT 411 418 variety variety NN 419 421 of of IN 422 426 Oct2 oct2 NN 427 435 isoforms isoform NNS 436 445 generated generate VBN 446 448 by by IN 449 460 alternative alternative JJ 461 469 splicing splicing NN 470 473 for for IN 474 477 the the DT 478 488 capability capability NN 489 491 to to TO 492 500 activate activate VB 501 503 an an DT 504 511 octamer octamer NN 512 520 enhancer enhancer NN 521 523 in in IN 524 535 nonlymphoid nonlymphoid JJ 536 541 cells cell NNS 542 545 and and CC 546 547 a a DT 548 554 B-cell b-cell NN 555 559 line line NN 559 560 . . . 561 564 Our our PRP$ 565 573 analyses analysis NNS 574 578 show show VBP 579 583 that that IN 584 591 several several JJ 592 596 Oct2 oct2 NN 597 605 isoforms isoform NNS 606 609 can can MD 610 619 stimulate stimulate VB 620 624 from from IN 625 626 a a DT 627 633 remote remote JJ 634 642 position position NN 643 646 but but CC 647 651 that that IN 652 656 this this DT 657 668 stimulation stimulation NN 669 671 is be VBZ 672 682 restricted restricted JJ 683 685 to to TO 686 687 B B NNP 688 693 cells cell NNS 693 694 . . . 695 699 This this DT 700 706 result result NN 707 716 indicates indicate VBZ 717 720 the the DT 721 732 involvement involvement NN 733 735 of of IN 736 742 either either CC 743 744 a a DT 745 760 B-cell-specific b-cell-specific JJ 761 769 cofactor cofactor NN 770 772 or or CC 773 774 a a DT 775 783 specific specific JJ 784 796 modification modification NN 797 799 of of IN 800 801 a a DT 802 810 cofactor cofactor NN 811 813 or or CC 814 817 the the DT 818 822 Oct2 oct2 NN 823 830 protein protein NN 831 833 in in IN 834 847 Oct2-mediated oct2-mediated JJ 848 856 enhancer enhancer NN 857 867 activation activation NN 867 868 . . . 869 879 Mutational mutational JJ 880 888 analyses analysis NNS 889 897 indicate indicate VBP 898 902 that that IN 903 906 the the DT 907 923 carboxy-terminal carboxy-terminal JJ 924 930 domain domain NN 931 933 of of IN 934 938 Oct2 oct2 NN 939 941 is be VBZ 942 950 critical critical JJ 951 954 for for IN 955 963 enhancer enhancer NN 964 974 activation activation NN 974 975 . . . 976 984 Moreover moreover RB 984 985 , , , 986 990 this this DT 991 997 domain domain NN 998 1007 conferred confer VBD 1008 1017 enhancing enhancing NN 1018 1026 activity activity NN 1027 1031 when when WRB 1032 1037 fused fuse VBN 1038 1040 to to TO 1041 1044 the the DT 1045 1049 Oct1 oct1 NN 1050 1057 protein protein NN 1057 1058 , , , 1059 1064 which which WDT 1065 1067 by by IN 1068 1074 itself itself PRP 1075 1078 was be VBD 1079 1085 unable unable JJ 1086 1088 to to TO 1089 1098 stimulate stimulate VB 1099 1103 from from IN 1104 1105 a a DT 1106 1112 remote remote JJ 1113 1121 position position NN 1121 1122 . . . 1123 1126 The the DT 1127 1141 glutamine-rich glutamine-rich JJ 1142 1152 activation activation NN 1153 1159 domain domain NN 1160 1167 present present JJ 1168 1170 in in IN 1171 1174 the the DT 1175 1189 amino-terminal amino-terminal JJ 1190 1197 portion portion NN 1198 1200 of of IN 1201 1205 Oct2 oct2 NN 1206 1209 and and CC 1210 1213 the the DT 1214 1217 POU POU NNP 1218 1224 domain domain NN 1225 1235 contribute contribute VBP 1236 1240 only only RB 1241 1251 marginally marginally RB 1252 1254 to to TO 1255 1258 the the DT 1259 1274 transactivation transactivation NN 1275 1283 function function NN 1284 1288 from from IN 1289 1290 a a DT 1291 1297 distal distal JJ 1298 1306 position position NN 1306 1307 . . .